TB-500

Overview

TB-500 is a laboratory-synthesized peptide corresponding to the sequence of Thymosin Beta-4, a member of a family of 16 highly conserved beta-thymosin peptides involved in cellular function. Its most studied property is its interaction with G-actin (monomeric actin), which it sequesters to regulate actin polymerization and availability within eukaryotic cells. Because actin can comprise up to 10% of total cellular protein content and is central to cell shape, movement, and division, compounds that modulate actin dynamics are of significant interest in cell biology research.

Preclinical research has examined TB-500 across several areas including angiogenesis, endothelial cell migration, extracellular matrix remodeling, and wound tissue research. Unlike many growth factors, TB-500 does not bind strongly to extracellular matrix proteins, and its relatively small molecular weight for a peptide of this length allows diffusion across tissue compartments in experimental settings.

Chemical Profile

Preclinical Research Findings

Actin Dynamics and Cell Migration Research

TB-500 has been studied in preclinical models for its role as an actin-sequestering peptide that regulates G-actin availability and influences cytoskeletal dynamics. Research has examined how TB-500 modulates actin polymerization through interaction with the WH2 domain motif (LKKTET), the minimal actin-binding sequence within the Thymosin Beta-4 structure. Preclinical studies have investigated its effects on endothelial cell migration and keratinocyte motility — cell types central to vascular and tissue research — and its influence on the production of matrix metalloproteinases involved in extracellular matrix remodeling. These properties have made TB-500 a research tool for studying the relationship between actin dynamics and directed cell movement in experimental tissue models.

Angiogenesis and Tissue Remodeling Research

Preclinical studies have identified TB-500 as a gene upregulated during early phases of blood vessel formation, and research has examined its role in angiogenesis — the process by which new blood vessels develop from existing vasculature. In preclinical wound models, TB-500 has been examined for its effects on wound fluid composition, endothelial sprouting, and collagen synthesis and deposition in connective tissue. Studies have also examined TB-500 for its effects on inflammatory mediators in joint and connective tissue models, with observations on inflammatory mediator expression reported in preclinical settings. Its presence in wound fluid and its influence on extracellular matrix composition have been examined in tissue biology and vascular research contexts.

Areas of Preclinical Research

• Actin sequestration and cytoskeletal dynamics studies
• Endothelial cell migration and angiogenesis research
• Extracellular matrix remodeling and collagen synthesis studies
• Anti-inflammatory pathway research in preclinical models
• Wound tissue biology and keratinocyte motility research

Research Use Only: This product is sold exclusively for laboratory and scientific research. It is not approved for human or veterinary use or consumption.

Disclaimer: All products distributed by Resolve Peptides are supplied exclusively for controlled laboratory and scientific research. They are not drugs, supplements, or therapies, and have not been approved by the FDA or any regulatory authority for human or veterinary use. These products are not intended for human or veterinary administration. Regulatory status of research peptides is subject to change; it is the responsibility of the researcher to verify current applicable regulations in their jurisdiction prior to purchase. Any references to biological effects are based solely on experimental and preclinical data.